Evidence map›Paper›PMID 28120497›Full record

Trial reportDiabetes, obesity & metabolism2017

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Bruce Neal, Vlado Perkovic, David R Matthews, Kenneth W Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Bruce NealThe George Institute for Global Health, Sydney, Australia.
Vlado PerkovicThe George Institute for Global Health, Sydney, Australia.
David R MatthewsUniversity of Oxford, Oxford, UK.
Kenneth W MahaffeyDepartment of Medicine, Stanford Center for Clinical Research (SCCR), Stanford University, Stanford, California.
Greg FulcherThe Royal North Shore Hospital, University of Sydney, Sydney, Australia.
Gary MeiningerJanssen Research & Development, LLC, Raritan, New Jersey.
Ngozi EronduJanssen Research & Development, LLC, Raritan, New Jersey.
Mehul DesaiJanssen Research & Development, LLC, Raritan, New Jersey.
Wayne ShawJanssen Research & Development, LLC, Raritan, New Jersey.
Frank VercruysseJanssen Research & Development, Beerse, Belgium.
Jacqueline YeeJanssen Research & Development, LLC, Raritan, New Jersey.
Hsiaowei DengJanssen Research & Development, LLC, Raritan, New Jersey.
Dick de ZeeuwUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
CANVAS-R Trial Collaborative Group
Janssen (United States) · USUniversity of Sydney · AUJanssen (Belgium) · BEStanford Medicine · USThe George Institute for Global Health · AUUniversity Medical Center Groningen · NLUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe primary aim of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) is to determine whether the favourable effects of inhibition of the sodium glucose co-transporter 2 (SGLT2) on blood glucose, blood pressure and body weight are accompanied by protection against adverse renal outcomes. MATERIALS AND

methodsCANVAS-R is a prospective, randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes with a history or high risk of cardiovascular events. Patients were randomly assigned to once-daily placebo or canagliflozin 100 mg (with optional uptitration to 300 mg) for a planned average of 2.5 years of follow-up. The primary outcome is kidney disease progression, defined by class change in albuminuria. The two secondary outcomes are the composite of hospitalized heart failure or cardiovascular death, and cardiovascular death alone. Effects on end-stage renal disease and a range of other outcomes will also be explored.

resultsA total of 5812 participants were recruited at 422 sites in 24 countries between January 2014 and May 2015. The mean baseline age was 64 years, mean duration of diabetes was 14 years, mean glycated haemoglobin level was 8.3% and mean body mass index was 32 kg/m

conclusionsThe trial should define the potential renoprotective effect of canagliflozin and will provide additional important new data about its effects on vascular outcomes, death and kidney failure.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAgedAlbuminuriaBlood GlucoseBlood PressureBody WeightCanagliflozinCardiovascular DiseasesComorbidityDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDouble-Blind MethodFemaleGlomerular Filtration RateHumansBlood GlucoseCanagliflozinHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorscardiovascular diseaseSGLT2 inhibitortype 2 diabetes

Identifiers

PMID28120497
PMCPMC5348724
OpenAlexW3021572394

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.